Based on our findings and discussions above, we predicted that the combined use of SHP2 and RAS/MAPK pathway inhibitors would also elicit this protective autophagy, and further, employment of an SHP2-AI with off-target autophagy inhibition properties would generate considerable benefits for cancer treatment. Here, PTPN11 is linked to cancer.